SecBot SecBot
SECBOTREPLAY Home › Report › APGE

APGE · Apogee Therapeutics reported full-year 2025 financial results with…

Apogee Therapeutics · PRESS-RELEASE filed Mar 2, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Mar 2, 2026 at 07:00 ET

Apogee Therapeutics reported full-year 2025 financial results with increased R&D and G&A spending driving a wider net loss, while maintaining a strong cash position of $902.9 million that funds operations into 2H 2028. The company highlighted upcoming clinical milestones for its lead asset zumilokibart in atopic dermatitis, asthma, and EoE, including a head-to-head trial against Dupixent with interim data expected in 2H 2026.

  • Cash, cash equivalents, and marketable securities totaled $902.9 million as of December 31, 2025, up from $731.1 million in 2024.
  • R&D expenses increased to $214.7 million in 2025 from $167.9 million in 2024.
  • G&A expenses rose to $70.9 million in 2025 from $49.0 million in 2024.
  • Net loss widened to $255.8 million in 2025 from $182.1 million in 2024.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access